Nicotine nasal spray for smoking cessation in primary care

Randomised placebo controlled trial of nicotine nasal spray for smoking cessation in primary care

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN03150596

Enrollment

1200

Registered

2010-04-15

Start date

1996-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tobacco dependence Mental and Behavioural Disorders Mental and behavioural disorders due to use of tobacco

Interventions

Active or placebo nicotine nasal spray for 12 weeks plus brief primary care counseling support. Total duration of follow-up is 12 weeks.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Smokers: smoking for at least 3 years 2. Aged 20 - 60 years, either sex 3. Smokes 15 or more cigarettes a day 4. Motivated to stop

Exclusion criteria

Exclusion criteria: 1. Myocardial infarction within 3 years 2. Chronic nasal disorder 3. Pregnancy, intending pregnancy 4. Breast feeding 5. Current psychiatric care 6. Current use of psychotropic drugs

Design outcomes

Primary

Measure	Time frame
Co-verified complete abstinence from smoking for weeks 3 to 12.	—

Secondary

Measure	Time frame
1. Co-verified complete abstinence from smoking during 12 weeks 2. Adverse events	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026